Mirum Pharmaceuticals (MIRM) Price & Analysis

Compare

695 Followers

MIRM Stock Chart & Stats

Day’s Range― - ―

52-Week Range$36.88 - $78.10

Previous CloseN/A

Volume92.82K

Average Volume (3M)827.38K

Market Cap

$3.67B

Enterprise Value$2.54B

Total Cash (Recent Filing)$304.55M

Total Debt (Recent Filing)$318.90M

Price to Earnings (P/E)―

Beta0.79

Next Earnings

Nov 12, 2025

EPS Estimate

-0.16

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.12

Shares Outstanding50,237,648

10 Day Avg. Volume485,283

30 Day Avg. Volume827,379

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.69

Enterprise Value/Revenue5.93

Enterprise Value/Gross Profit7.50

Enterprise Value/Ebitda-135.43

Forecast

1Y Price Target

$80.45

Price Target Upside9.99% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering11

Bulls Say, Bears Say

Bulls Say

EarningsMirum reported another strong Livmarli quarter with $88mm in sales, beating analyst and consensus estimates by over 20%.

Financial PerformanceMIRM has executed well in establishing a sizable, cash-flow positive business with significant revenue growth projections.

Product ExpansionManagement believes a potential label expansion for Livmarli to patients with other ultra-rare cholestatic diseases could propel the drug to blockbuster status.

Bears Say

CompetitionEven with competition, volixibat is seen as well-positioned in large rare diseases, with its potential to differentiate on efficacy and benefit from market developments.

Mirum Pharmaceuticals News

Mirum Pharmaceuticals price target raised to $77 from $53 at JPMorgan

JPMorgan raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $77 from $53 and keeps an Overweight...

7d ago

MIRM

Mirum Pharmaceuticals completes enrollment in VISTAS study of volixibat

Mirum Pharmaceuticals (MIRM) announced the completion of enrollment in the Phase 2b VISTAS study of volixibat, an investigational...

11d ago

MIRM

Mirum Pharmaceuticals’ Volixibat Study: A Potential Game-Changer for PBC Treatment

Mirum Pharmaceuticals (($MIRM)) announced an update on their ongoing clinical study. Mirum Pharmaceuticals is conducting a study titled...

28d ago

MIRM

Mirum Pharmaceuticals’ Volixibat Study: A Potential Game-Changer for PSC Treatment

Mirum Pharmaceuticals (($MIRM)) announced an update on their ongoing clinical study. Mirum Pharmaceuticals is conducting a clinical study...

29d ago

MIRM

Mirum Pharmaceuticals files automatic mixed securities shelf

16:08 EDT Mirum Pharmaceuticals (MIRM) files automatic mixed securities shelf Published first on TheFly – the ultimate source...

1M ago

MIRM

Arm initiated, Adobe downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

1M ago

ARM

Mirum Pharmaceuticals resumed with a Buy at Stifel

Stifel analyst James Condulis resumed coverage of Mirum Pharmaceuticals (MIRM) with a Buy rating and $89 price target...

1M ago

MIRM

Mirum Pharmaceuticals: Strong Buy Rating Backed by Robust Growth Prospects in Rare Disease Market

James Condulis, an analyst from Stifel Nicolaus, has initiated a new Buy rating on Mirum Pharmaceuticals (MIRM). James...

1M ago

MIRM

Buy Rating Affirmed for Mirum Pharmaceuticals Amid Strong Financial Performance and Growth Potential

Mirum Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst on August 6. Analyst Mani...

1M ago

MIRM

Mirum Pharmaceuticals Reports Strong Q2 Growth and Raises Guidance

Mirum Pharmaceuticals (($MIRM)) has held its Q2 earnings call. Read on for the main highlights of the call....

1M ago

MIRM

Mirum Pharmaceuticals price target raised to $82 from $77 at Raymond James

Raymond James raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $82 from $77 and keeps a...

1M ago

MIRM

Mirum Pharmaceuticals price target raised to $81 from $79 at Citizens JMP

Citizens JMP analyst Jonathan Wolleben raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $81 from $79...

1M ago

MIRM

Mirum Pharmaceuticals price target raised to $80 from $73 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $80 from $73 and keeps a...

1M ago

MIRM

Strong Commercial Performance and Strategic Initiatives Drive Buy Rating for Mirum Pharmaceuticals

Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on Mirum Pharmaceuticals. The associated price target...

1M ago

MIRM

MIRM FAQ

What was Mirum Pharmaceuticals Inc’s price range in the past 12 months?

Mirum Pharmaceuticals Inc lowest stock price was $36.88 and its highest was $78.09 in the past 12 months.

What is Mirum Pharmaceuticals Inc’s market cap?

Mirum Pharmaceuticals Inc’s market cap is $3.67B.

When is Mirum Pharmaceuticals Inc’s upcoming earnings report date?

Mirum Pharmaceuticals Inc’s upcoming earnings report date is Nov 12, 2025 which is in 54 days.

How were Mirum Pharmaceuticals Inc’s earnings last quarter?

Mirum Pharmaceuticals Inc released its earnings results on Aug 06, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.326 by $0.206.

Is Mirum Pharmaceuticals Inc overvalued?

According to Wall Street analysts Mirum Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Mirum Pharmaceuticals Inc pay dividends?

Mirum Pharmaceuticals Inc does not currently pay dividends.

What is Mirum Pharmaceuticals Inc’s EPS estimate?

Mirum Pharmaceuticals Inc’s EPS estimate is -0.16.

How many shares outstanding does Mirum Pharmaceuticals Inc have?

Mirum Pharmaceuticals Inc has 50,237,648 shares outstanding.

What happened to Mirum Pharmaceuticals Inc’s price movement after its last earnings report?

Mirum Pharmaceuticals Inc reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.326. Following the earnings report the stock price went up 12.043%.

Which hedge fund is a major shareholder of Mirum Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in MIRM

Mirum Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

-24.19%

Trailing 12-Months

Asset Growth

9.85%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with rare liver diseases. The company is primarily engaged in the development of treatments that address unmet medical needs in the field of hepatology. Its core products include Maralixibat, a drug designed for the treatment of cholestatic liver diseases, and other candidates targeting various liver conditions.

Mirum Pharmaceuticals (MIRM) Earnings & Revenues

Historic Earnings Reports

MIRM Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a strong performance by Mirum Pharmaceuticals, highlighted by significant revenue growth and positive pipeline developments. While there are challenges such as high operating expenses and variability in international sales, the positive aspects significantly outweigh the negatives.View all MIRM earnings summaries

MIRM Stock 12 Month Forecast

Average Price Target

$80.45

▲(9.99% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"39":"$39","90":"$90","51.75":"$51.8","64.5":"$64.5","77.25":"$77.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":89,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$89.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":80.45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$80.45</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":66,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$66.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[39,51.75,64.5,77.25,90],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,74.34,75.46769230769232,76.59538461538462,77.72307692307693,78.85076923076923,79.97846153846154,81.10615384615384,82.23384615384616,83.36153846153846,84.48923076923077,85.61692307692307,86.74461538461539,87.87230769230769,{"y":89,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,74.34,74.81,75.28,75.75,76.22,76.69,77.16,77.63000000000001,78.10000000000001,78.57000000000001,79.04,79.51,79.98,{"y":80.45,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,74.34,73.69846153846154,73.05692307692308,72.41538461538462,71.77384615384615,71.13230769230769,70.49076923076923,69.84923076923077,69.20769230769231,68.56615384615385,67.92461538461538,67.28307692307692,66.64153846153846,{"y":66,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":40.13,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.12,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.4,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.21,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.88,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.57,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.04,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.42,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.39,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.34,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >